Moleculin Biotech Net Income Over Time
| MBRX Stock | USD 4.14 0.02 0.49% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Moleculin Biotech Performance and Moleculin Biotech Correlation. Moleculin | Build AI portfolio with Moleculin Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. Expected growth trajectory for Moleculin significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Moleculin Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Moleculin Biotech requires distinguishing between market price and book value, where the latter reflects Moleculin's accounting equity. The concept of intrinsic value - what Moleculin Biotech's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Moleculin Biotech's price substantially above or below its fundamental value.
Understanding that Moleculin Biotech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Moleculin Biotech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Moleculin Biotech's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Moleculin Biotech and related stocks such as Apollomics Class A, Athira Pharma, and SeaStar Medical Holding Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APLM | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (74.8 M) | (94.8 M) | (240.8 M) | (172.6 M) | (53.9 M) | (48.5 M) | (50.9 M) |
| ICU | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (4.6 M) | (23 M) | (26.2 M) | (24.8 M) | (22.3 M) | (23.5 M) |
| LNAI | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (113.4 M) | (39.7 M) | (88.4 M) | (178 M) | (160.2 M) | (152.2 M) |
| CTXR | (26.3 K) | (22 K) | (31.4 K) | (1.3 M) | (2.9 M) | (8.3 M) | (10.4 M) | (12.5 M) | (15.6 M) | (17.5 M) | (23.1 M) | (33.6 M) | (32.5 M) | (39.1 M) | (37.4 M) | (33.7 M) | (32 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| AIMD | (300 K) | (1.3 M) | (650.8 K) | (622.6 K) | (622.6 K) | (521.9 K) | (670 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (13.8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| BLRX | (32.1 M) | (13.2 M) | (20.4 M) | (17.6 M) | (10.2 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
Moleculin Biotech and related stocks such as Apollomics Class A, Athira Pharma, and SeaStar Medical Holding Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Moleculin Biotech financial statement analysis. It represents the amount of money remaining after all of Moleculin Biotech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Moleculin Biotech | MBRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 5300 Memorial Drive, |
| Exchange | NASDAQ Exchange |
USD 4.14
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.